Chemical Proteomics Technologies
Cellzome is a pioneer in the development and advancement of chemical proteomics technologies.
We are using Kinobeads™ and Episphere™, our world-leading chemical proteomics technologies, to identify drug candidates which target selectively kinases or epigenetic enzymes to treat inflammatory disease.
Chemical proteomics studies the effects of active small molecules on the proteome, the protein content of a cell or tissue type. We use chemical proteomics in a quantitative way at various stages in the drug discovery process, from screening to selectivity profiling of drugs in different cells and also patient samples. While Kinobeads™ is used for the identification and optimization of kinase inhibitors, Episphere™ addresses epigenetic target classes, with the goal of developing novel drug candidates which inhibit epigenetic enzymes in their disease-relevant complexes.
We are also applying our pathway mapping technology for the characterization of multi-protein complexes. Understanding the composition of these complexes is particularly important for epigenetic targets, since these enzymes are regulated and targeted to their site of action by proteins in large complexes.
Cellzome has published a number of peer-reviewed landmark publications (e.g. Bantscheff et al. Nature Biotechnology 25 2007, Bouwmeester et al. Nature Cell Biology 6 2004 and Gavin et al. Nature 415 2002) which describe these methodologies in more detail.